The emergence of dual-action receptor agonists in the approach of type 2 diabetes and obesity has sparked considerable focus, particularly regarding retatrutide and tirzepatide. While both medications target both the https://janeyytf745835.newsbloger.com/39523096/retatrutide-vs-tirzepatide-a-comparative-analysis